×

Publications Related to DecisionDx®-Melanoma

DecisionDx-Melanoma Clinical Validity to Identify Patients at Low Risk for SLN Positivity

Cook RW, Monzon FA, Caruso HG, et al. Identification of melanoma patients with low risk of sentinel lymph node positivity and favorable prognosis using a 31-gene expression profile (GEP) test. Poster at Society for Melanoma Research (SMR) Congress: Nov 20-23, 2019; Salt Lake City, Utah.

DecisionDx-Melanoma Clinical Validity and Performance Studies to Predict Risk of Recurrence

Keller J, Schwartz TL, Lizalek JM, et al. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. Cancer Med 2019;8:2205-12.

Gastman BR, Zager JS, Messina JL, et al. Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck. Head Neck 2019;41:871-9.

Leachman S, Covington KR, Cook RW, et al. Implications of a 31-gene expression profile test for cutaneous melanoma on AJCC-based risk assessment and adjuvant therapy trial design. Poster presented at 2018 Society for Melanoma Research International Congress.

Greenhaw BD, Zitelli JA, Brodland DG. Estimation of prognosis in invasive cutaneous melanoma: An independent study of the accuracy of a gene expression profile test. Dermatol Surg 2018;44:1494-1500. doi: 10.1097/DSS.0000000000001588.

Gerami P, Cook RW, Russell MC, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients with sentinel lymph node biopsy. J Am Acad Dermatol 2015;72:780-5.e3.

DecisionDx-Melanoma Clinical Impact Studies

Berger AC, Davidson RS, Poitras JK, et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. Curr Med Res Opin 2016;32:1599-1604. doi:10.1080/03007995.2016.1192997.

Systematic Reviews & Guidelines

Dubin DP, Dinehart SM & Farberg AS. Level of evidence review for a gene expression profile test for cutaneous melanoma. Am J Clin Dermatol 2019;20:763-70.

Winkelmann RR, Farberg AS, Glazer AM, et al. Integrating skin cancer-related technologies into clinical practice. Dermatol Clin 2017;35:565-76.

DecisionDx-Melanoma Analytic Validity

Cook RW, Middlebrook B, Wilkinson J, et al. Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients. Diagn Pathol 2018;13:13. doi:10.1186/s13000-018-0690-3.

Recent DecisionDx-Melanoma Presentations and Posters

Cook RW, Monzon FA, Caruso HG, et al. Identification of melanoma patients with low risk of sentinel lymph node positivity and favorable prognosis using a 31-gene expression profile (GEP) test. Poster at Society for Melanoma Research (SMR) Congress: Nov 20-23, 2019; Salt Lake City, Utah.

Monzon FA, Caruso HG, Covington KR, et al. Identification of T1-T2 melanoma patients at low risk for a positive sentinel lymph node using the 31-gene expression profile test. Oral presentation at 8th International Congress on Cancer Metastasis (ICCM): October 25-27, 2019; San Francisco, California.

Thorpe R, Covington K, Caruso H, et al. Development and validation of a clinically useful nomogram incorporating molecular clinicopathologic factors to predict risk of recurrence in patients with cutaneous melanoma. Oral presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting, October 24-27, 2019; Chicago, Illinois.

Estrada S, Covington KR, Caruso HG, et al. Identification of T1 melanoma patients at low risk for a positive sentinel lymph node (SLN) using a 31-gene expression profile (31-GEP). Poster at American Society of Dermatopathology (ASDP) 56th Annual Meeting: October 17-20, 2019; San Diego, California.

Prado G, Teplitz RW, Covington KR, et al. The prognostic 31-gene expression profile (31-GEP) test improves risk prediction in cutaneous melanoma (CM) patients within current AJCC stages. Poster at 2019 Fall Clinical Dermatology Conference for PAs and NPs: May 31-June 2, 2019; Scottsdale, Arizona.

Greenhaw B, Hsueh EC, Covington KR, et al. Meta-analysis of the prognostic 31-gene expression profile test in 1261 cutaneous melanoma cases. Late breaking research presented at 2019 American Academy of Dermatology Annual Meeting: March 1-5, 2019; Washington DC.

Cook RW, Monzon FA, Hyams D. A retrospective case series to evaluate the clinical utility of a 31-gene expression profile test in cutaneous melanoma patients. SKIN J Cutan Med 2018;2:S44. Poster at 2018 Winter Clinical Dermatology Conference: Jan 12-17, 2019; Lahaina, Hawaii.

Melanoma Background

Poklepovic AS, Carvajal RD. Prognostic value of low tumor burden in patients with melanoma. Oncology 2018;32:e90-e96.

Farberg AS, Glazer AM, Winkelmann RR, et al. Assessing genetic expression profiles in melanoma prognosis. Dermatol Clin 2017;35:545-50.

Winkelmann RR, Farberg AS, Glazer AM, et al. Noninvasive technologies for the diagnosis of cutaneous melanoma. Dermatol Clin 2017;35:453-6.

Livingstone E, Krajewski C, Eigentler TK, et al. Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicenter and longitudinal study. Eur J Cancer 2015;51:653-67.

Publications Related to DecisionDx®-UM

Aaberg, et al. (2014). Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. Clinical Opthalmology, 8, 2449-60.

Aaberg (2012). Practical approaches to needle biopsy and genetic diagnosis for ocular melanoma. Retina 2012: The Winds of Change. Lecture conducted from The American Academy of Ophthalmology, Chicago, IL.

Chappell, et al. (2012). Uveal Melanoma: molecular pattern, clinical features, and radiation response. American Journal of Ophthalmology, 227-32.

Correa & Augsburger. (2016). Independent prognostic significance of gene expression profile class and largest basal diameter of posterior uveal melanomas. American Journal of Ophthalmology, 162, 20-27 e1.

Correa & Augsburger. (2014). Sufficiency of FNAB aspirates of posterior uveal melanoma for cytologic versus GEP classification in 159 patients, and relative prognostic significance of these classifications. Graefe's Archive for Clinical and Experimental Ophthalmology, 252(1), 131-5.

Demirci, et al. (2015). Gene expression profiling test of uveal melanoma: prognostic validation, in American Society of Ophthalmic Plastic & Reconstructive Surgery Fall Scientific Symposium: Las Vegas, NV.

Field & Harbour. (2014). Recent developments in prognostic and predictive testing in uveal melanoma. Current Opinion in Ophthalmology, 25(3), 234-9.

Gill & Char. (2012). Uveal melanoma prognostication: from lesion size and cell type to molecular class. Canadian Journal of Ophthalmology, 47, 246-253.

Harbour (2011). Molecular research in uveal melanoma: ushering in a new standard of care. Retina Times, 29, 36-7.

Harbour (2010). Genomic Research in Uveal Melanoma. Retina Today, 67-69.

Harbour & Chen. (2013). The DecisionDx-UM gene expression profile test provides risk stratification and individualized patient care in uveal melanoma. PLOS Currents Evidence on Genomic Tests. 2013 Apr 9 [last modified: 2013 Apr 9]. Edition 1.

Onken, et al. (2012). Collaborative Ocular Oncology Group Report Number 1: Prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophth, epub. The Collaborative Ocular Melanoma Study: An Overview.

Onken, et al. (2010). An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. Journal of Molecular Diagnostics, 12(4), 461-8.

Onken, et al. (2006). Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens. Journal of Molecular Diagnostics, 8, 567-73.

Plasseraud, et al. (2016). Clinical performance and management outcomes with the DecisionDx-UM gene expression profile test in a prospective multicenter study. Journal of Oncology, 2016. doi:10.1155/2016/5325762.

Onken, et al. (2004). Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Research, 64, 7205-9.

Worley, et al. (2007). Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clinical Cancer Research, 13(5), 1466-71.

Field, et al. (2016). Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas. Oncotarget, 7, 59209-19.

Publications Related to DecisionDx®-PRAME

Field, et al. (2016). PRAME as an independent biomarker for metastasis in uveal melanoma. Clinical Cancer Research, 22, 1234-42.

Walter, et al. (2016). Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma. JAMA Ophthalmology, 134(7), 734-40.

Scroll to Top